1. Single-Dose Neoadjuvant AKT Pathway Inhibitor Reduces Growth of Hepatocellular Carcinoma after Laser Thermal Ablation in a Small
Animal Model 
Neoadjuvant PI3K/mTOR/AKT inhibitor prior to laser thermal ablation reduced postablation tumor growth by 37%–75% (P < .001 to P = .04) in a mouse model of hepatocellular carcinoma (HCC).
Neoadjuvant PI3K/mTOR/AKT inhibitor reversed the global effects of moderate heat stress on HCC molecular signaling and cellular function, including activation of cell survival, growth, proliferation, invasion, and metastasis in addition to inhibition of cell death and apoptosis.
Jondal DE et al. Published Online: July 23, 2019